Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatotoxicity of alogliptin.

× No keyword cloud information.

3 in total

1. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors: William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245

Review 2. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.

Authors: Lesley J Scott
Journal: Drugs Date: 2010-10-22 Impact factor: 9.546

Review 3. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors: André J Scheen
Journal: Clin Pharmacokinet Date: 2014-09 Impact factor: 6.447

3 in total

6 in total

1. Alogliptin: concern about hepatotoxicity?

Authors: André J Scheen
Journal: Clin Pharmacokinet Date: 2014-11 Impact factor: 6.447

2. Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Authors: Emanuel Raschi; Elisabetta Poluzzi; Fabrizio De Ponti
Journal: Clin Pharmacokinet Date: 2015-04 Impact factor: 6.447

3. Author's reply to De Ponti et al.: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus".

Authors: André J Scheen
Journal: Clin Pharmacokinet Date: 2015-04 Impact factor: 6.447

Review 4. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.

Authors: Emanuel Raschi; Fabrizio De Ponti
Journal: World J Hepatol Date: 2015-07-08

Review 5. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.

Authors: Carolyn F Deacon
Journal: Nat Rev Endocrinol Date: 2020-09-14 Impact factor: 43.330

Review 6. Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.

Authors: Kohei Kaku; Koichi Kisanuki; Mari Shibata; Takashi Oohira
Journal: Drug Saf Date: 2019-11 Impact factor: 5.606

6 in total